Umeclidinium bromide/vilanterol
| 
 Umeclidinium bromide (TOP), vilanterol (BOTTOM) | |
| Combination of | |
|---|---|
| Umeclidinium bromide | Muscarinic antagonist | 
| Vilanterol | Ultra-long-acting β2 agonist | 
| Clinical data | |
| Trade names | Anoro Ellipta | 
| AHFS/Drugs.com | anoro-ellipta | 
| Pregnancy category | 
 | 
| Routes of administration | Inhalation (DPI) | 
| ATC code | R03AL03 (WHO) | 
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.
References
- ↑ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
- ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
This article is issued from Wikipedia - version of the 4/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
